US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Indaptus Therapeutics Inc (INDP)
Indaptus Therapeutics Inc (INDP) ニュース

INDP

Indaptus Therapeutics (INDP)

Indaptus Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:INDP

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/22	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/05/22	21 : 00	GlobeNewswire Inc.	Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/05/08	21 : 06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/05/08	21 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/05/08	21 : 00	GlobeNewswire Inc.	Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/04/11	20 : 30	GlobeNewswire Inc.	Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/03/28	21 : 00	GlobeNewswire Inc.	Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/03/25	21 : 30	GlobeNewswire Inc.	Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/03/18	21 : 00	GlobeNewswire Inc.	Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/03/13	20 : 30	GlobeNewswire Inc.	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/03/05	01 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/03/04	21 : 30	GlobeNewswire Inc.	Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/02/15	22 : 00	GlobeNewswire Inc.	Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/02/08	22 : 00	GlobeNewswire Inc.	Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/01/24	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/01/24	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2024/01/04	22 : 00	GlobeNewswire Inc.	European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/11/07	06 : 06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/11/07	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/11/07	06 : 01	GlobeNewswire Inc.	Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/11/06	22 : 13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/11/06	22 : 00	GlobeNewswire Inc.	Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/10/31	22 : 12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/10/31	22 : 01	GlobeNewswire Inc.	Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/09/27	21 : 00	GlobeNewswire Inc.	Indaptus Therapeutics to Present at the LD Micro Main Event XVI	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/09/26	21 : 00	GlobeNewswire Inc.	Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/09/19	21 : 00	GlobeNewswire Inc.	Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/09/06	21 : 05	GlobeNewswire Inc.	Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/08/17	07 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INDP	Indaptus Therapeutics Inc
2023/08/14	21 : 15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:INDP	Indaptus Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:INDP

1 2 3 4 5 次へ >>

US Dollar vs Yen

Bank of America

US Dollar vs Sterling

US Dollar vs Euro

Invesco QQQ Trust Series 1

Verizon Communications

Financial Select Sector

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約